Specific Clinical Scenario

Hirsutism with Obesity or Age Over 39 — Initial Therapy When Venous Thromboembolism Risk Is Elevated

Women with hirsutism who are obese or aged over 39 years carry a meaningfully higher baseline risk for venous thromboembolism. This risk profile directly shapes which initial hormonal therapy is appropriate, and requires a more selective approach than in lower-risk patients.

Clinical Scenario

Hirsutism in a patient with obesity or age over 39 years — recognised risk factors for venous thromboembolism that must be weighed when selecting initial hormonal treatment.

Treatment Approach (partial)

Initial therapy is built around a particular oral contraceptive formulation chosen to keep thrombotic risk as low as possible. The criteria governing which formulation qualifies — including the oestrogen dose level and the progestin category — are specific to this higher-risk population.

Full formulation criteria, decision algorithm, and monitoring details are in the structured protocol below.

Treatment Goal

The clinical target is a measurable improvement in hirsutism, assessed as a reduction in the Ferriman–Gallwey hirsutism score. A detectable response typically requires approximately 6 months of hormonal therapy; maximal effects take longer still to appear.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1210/jc.2018-00241

For women with hirsutism at higher risk for VTE (e.g., those who are obese or over age 39 years), we suggest initial therapy with an OC containing the lowest effective dose of ethinyl estradiol (EE) (usually 20 mcg) and a low-risk progestin (Table 2). (2 |OOO)

Due to the long hair growth cycle, it takes ~6 months to detect the effects of hormonal therapy and ~9 months for these effects to become maximal.

View source ↗